OncoLink Cancer Resource Newsletter
OncoLink Cancer Resource Newsletter
OncoLink Cancer Resource Newsletter
November, 2004 OncoLink Cancer Resource Newsletter Sponsored by Aventis Oncology
In this Issue

Scientific Findings: Special reports on lung cancer from the 2004 American Society of Clinical Oncology (ASCO) and the American Society of Therapeutic Radiology and Oncology Annual Meetings (ASTRO)

OncoLink Cancer Resource Newsletter Neoadjuvant Chemotherapy Followed by Preoperative Radiochemotherapy (hfRTCT) Plus Surgery or Surgery Plus Postoperative Radiotherapy in Stage III Non-Small Cell Lung Cancer: Results of a Randomized Phase III Trial of the German Lung Cancer Cooperative Group
OncoLink Cancer Resource Newsletter A multicenter, phase III randomized trial for stage IIIb/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel
OncoLink Cancer Resource Newsletter

A prospective randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non-small cell lung cancer. Intergroup JBR10

OncoLink Cancer Resource Newsletter Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633
OncoLink Cancer Resource Newsletter Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) : 'the "LUCAS" study
OncoLink Cancer Resource Newsletter Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
OncoLink Cancer Resource Newsletter Traditional versus up-front 18-FDG PET staging of non-small cell lung cancer (NSCLC): A Dutch Co-operative randomized study

Transdisciplinary Tobacco Use Research Center: Formed to obtain a more complete understanding of the role of specific genetic factors and bio-behavioral mechanisms in tobacco addiction, and to translate this knowledge to develop more effective tobacco dependence treatments.

Volunteers Needed: Interested in participating in research on tobacco use? See more information about research projects seeking volunteers.

OncoLink SurveyNutrition Information Available During Treatment Survey Please take a moment to fill out this anonymous survey. We are collecting information to better understand the use of therapies by oncology patients that are not typically prescribed by doctors or given in hospitals for cancer treatment.

OncoLink PollOncoLink Monthly Poll: What is your smoking status?

 

November is ...

Lung Cancer Awareness Month OncoLink Cancer Resource Newsletter
Join OncoLink in helping to educate the public about the importance of prevention, treatment and research advances made to eliminate this disease. Visit our Lung Cancer Menu for more information.


OncoLink NewsFlash

More Reasons to Quit
Senior Editor, Julia Draznin Maltzman, MD gives us five new reasons to break the habit. Just in case heart disease, peripheral vascular disease, emphysema, and lung and head and neck cancers were not good enough reasons to quit smoking, the US Surgeon General's office added five more cancers to the risk of diseases caused by cigarettes.


OncoLink Editors Choice

Editor's Choice Award November, 2004
LungCancer.org is dedicated to improving care for those with lung cancer by disseminating up-to-date and accurate information that encourages early diagnosis; shares developments in screening and treatment; and offers support to lung cancer patients and their loved ones.


Ask The Experts about Lung Cancer
This is your chance to "Ask the OncoLink Experts" everything you've always wanted to know about cancer.

 

Contact Us | Unsubscribe | Privacy Policy